Novartis | NVS - Operating Profit


Novartis reported $1.84B in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bausch Health Companies USD 993M 217M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -17.58M 9.9M Jun/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Drreddys Laboratories INR 12.81B 11.98B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.13B 166M Sep/2026
J&J USD 6.47B 1B Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 3.7M Sep/2026
Pfizer USD 662M 5M Sep/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Sanofi EUR 2.38B 115M Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Zoetis USD 1.03B 88M Sep/2026